Biotech RadarJobs updated

COMPANY

Dyne Therapeutics

HQ: Waltham, MA source · dyne-tx.com ↗ · New England

Clinical Phase 3

36 open jobs · last seen Oct 23, 2026 · 9 sources

Dyne created the FORCETM platform to develop therapeutics that address the root cause of disease and deliver functional improvement for people living with neuromuscular disorders. Our proprietary Fab binds to transferrin receptor 1 (TfR1) to enable delivery to muscle and the central nervous system (CNS) with the goal of providing functional improvement for people living with neuromuscular diseases. From company website Source · Oct 13, 2026

Keywords: therapeutics forcetm neuromuscular transferrin receptor Duchenne muscular dystrophy myotonic dystrophy type 1 facioscapulohumeral muscular dystrophy Myotonic Dystrophy Type 1 (DM1) DM1 Steinert Disease Steinert Muscular Dystrophy (DMD) DMD Muscular Dystrophies Duchenne Type Muscular Dystrophy Duchenne and Becker Types Muscular Dystrophy Muscular Dystrophies (Duchenne, Becker, Myotonic Dystrophy) Inborn Genetic Disease X-Linked Genetic Disease Congenital, Hereditary, and Neonatal Diseases and Abnormalities Neuromuscular Diseases zeleciment basivarsen (DYNE-101) DYNE-101 DYNE-251 Zeleciment Rostudirsen (DYNE-251)

Profile checked Oct 10, 2026

Since the raise (Jul 21, 2026): 36 of 36 open jobs were first seen after it.

36Open jobs$1.0BRaised (2 yrs)4Trials (company is sponsor)

Hiring

TitleLocation (from posting)Employer postedFirst seen
Associate Director, Analytical DevelopmentWaltham, MAOct 20, 2026Oct 21, 2026
Director, Government Pricing & Contract OperationsWaltham, MAOct 16, 2026Oct 17, 2026
Senior Director, Medical Affairs BiostatisticsWaltham, MAOct 9, 2026Oct 9, 2026
Associate Director, Regulatory Operations - Veeva Vault RIMRemoteOct 6, 2026Oct 7, 2026
Associate Director, Financial Planning & Analysis (FP&A)Waltham, MAOct 6, 2026Oct 6, 2026

See all 36 jobs

Timeline

  1. Board tracked Radar started tracking this company’s job board (36 open jobs at last check). source ↗
  2. Raise Follow-on offering: $431.4M (closed, incl. full underwriter option), announced Jul 21, 2026. Source: SEC filing. source ↗
  3. Trial start Phase 3: Efficacy, Safety, and Tolerability of Zeleciment Rostudirsen (DYNE-251) Administered Intravenously Every 4 Weeks in Ambulatory Participants With Duchenne Muscular Dystrophy (FORZETTO) source ↗
  4. Trial start Phase 3: Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1 source ↗
  5. Raise Follow-on offering: $402.5M (total, as published), announced Dec 11, 2025. Source: company release on GlobeNewswire. source ↗
  6. Raise Follow-on offering: $230M (total, as published), announced Jul 2, 2025. Source: company release on GlobeNewswire. source ↗
  7. Debt Debt financing: $275M (up to, as announced), announced Jun 30, 2025. Source: company release on GlobeNewswire. source ↗
  8. Trial start Phase 1/Phase 2: Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-101 in Participants With Myotonic Dystrophy Type 1 source ↗
  9. Trial start Phase 1/Phase 2: Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-251 in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Open jobs 36

TitleLocation (from posting, not HQ)Employer postedFirst seenLevel
Associate Director, Analytical DevelopmentWaltham, MAOct 20, 2026Oct 21, 2026Not stated
Director, Government Pricing & Contract OperationsWaltham, MAOct 16, 2026Oct 17, 2026Not stated
Senior Director, Medical Affairs BiostatisticsWaltham, MAOct 9, 2026Oct 9, 2026Senior
Associate Director, Regulatory Operations - Veeva Vault RIMRemoteOct 6, 2026Oct 7, 2026Senior
Associate Director, Financial Planning & Analysis (FP&A)Waltham, MAOct 6, 2026Oct 6, 2026Senior
Director, Cost AccountingWaltham, MAOct 6, 2026Oct 6, 2026Senior
Director, RevenueWaltham, MAOct 6, 2026Oct 6, 2026Senior
Associate Director, Market Research & Competitive IntelligenceWaltham, MASep 29, 2026Oct 5, 2026Senior
Associate Director, Medical Information and ReviewWaltham, MASep 29, 2026Oct 5, 2026Senior
Senior Director, Financial Planning & Analysis - R&DWaltham, MASep 28, 2026Oct 5, 2026Senior
Senior Administrative Assistant - US AffiliateWaltham, MASep 17, 2026Oct 5, 2026Senior
Executive AssistantWaltham, MASep 17, 2026Oct 5, 2026Senior
Associate Director, Clinical Operations Study LeadWaltham, MASep 11, 2026Oct 5, 2026Senior
Executive Director, TechOps Alliance and Strategic PartnershipsWaltham, MASep 9, 2026Oct 5, 2026Executive
Senior Director, Quality ControlWaltham, MASep 8, 2026Oct 5, 2026Senior
Senior Director, Medical Affairs Learning & DevelopmentWaltham, MA Aug 31, 2026Oct 5, 2026Senior
Director, Clinical ScientistWaltham, MAAug 28, 2026Oct 5, 2026Senior
Scientist, BioconjugationWaltham, MAAug 28, 2026Oct 5, 2026Senior
Director, Drug Safety & Pharmacovigilance ScientistWaltham, MAAug 20, 2026Oct 5, 2026Senior
Director, People OperationsWaltham, MAAug 17, 2026Oct 5, 2026Senior
Associate Director, Talent Acquisition Operations & ProgramsWaltham, MAAug 13, 2026Oct 5, 2026Senior
Senior Director, Business Strategy & Operations - Office of the CCOWaltham, MAAug 11, 2026Oct 5, 2026Executive
Medical Director, Clinical DevelopmentWaltham, MAJul 31, 2026Oct 5, 2026Senior
Thought Leader Liaison - NortheastField-BasedJul 20, 2026Oct 5, 2026Senior
VP, Learning & Leadership DevelopmentWaltham, MAJul 16, 2026Oct 5, 2026Executive
Associate Director, Quality Management SystemsWaltham, MAJul 7, 2026Oct 5, 2026Senior
Dyne Care Partner - NorthwestField-BasedJul 6, 2026Oct 23, 2026Not stated
Key Account Manager - Great LakesField-BasedJul 6, 2026Oct 5, 2026Senior
Director, Medical WritingRemoteJul 2, 2026Oct 5, 2026Senior
Director, Medical WritingRemoteJul 2, 2026Oct 5, 2026Senior
Senior Manager, US Medical AffairsWaltham, MAJun 29, 2026Oct 5, 2026Senior
VP, DM1 Commercial Asset LeadWaltham, MAJun 17, 2026Oct 5, 2026Executive
Executive Director, Regulatory AffairsWaltham, MAMay 27, 2026Oct 5, 2026Executive
Associate Director, Formulation and Drug Product DevelopmentWaltham, MAApr 3, 2026Oct 5, 2026Senior
Senior Director, Program ManagementWaltham, MAMar 16, 2026Oct 5, 2026Senior
Director, QA GMP OperationsWaltham, MADec 24, 2025Oct 5, 2026Senior

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

Funding

Raised: $1.1B · Debt: $275.0M. Last 2 years.

Clinical trials (lead sponsor) 4

RecordTitlePhaseStatusStartPrimary completion
NCT07486934Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1Phase 3RecruitingMay 14, 20262028-07 (estimated)
NCT05481879Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-101 in Participants With Myotonic Dystrophy Type 1Phase 1/Phase 2Active, not recruitingSep 5, 20222029-07 (estimated)
NCT05524883Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-251 in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 SkippingPhase 1/Phase 2Active, not recruitingAug 12, 20222031-09 (estimated)
NCT07608432Efficacy, Safety, and Tolerability of Zeleciment Rostudirsen (DYNE-251) Administered Intravenously Every 4 Weeks in Ambulatory Participants With Duchenne Muscular Dystrophy (FORZETTO)Phase 3Recruiting2026-062030-12 (estimated)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

Connect

See your connections at Dyne Therapeutics on LinkedIn (search by name, results not checked)

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-18

Feedback